Search for Terms or Answers
Eli Lilly and Company (NYSE: LLY) announced that it will present new data for baricitinib and Taltz® (ixekizumab) at the American College of Rheumatology (ACR)/Association of Rheumatology Health Professionals (ARHP) annual meeting taking place Nov. 3-8, 2017, in San Diego, Calif.
Crescendo Bioscience, a wholly-owned subsidiary of Myriad Genetics, Inc. (NASDAQ:MYGN), today announced that six studies on Vectra® DA will be featured at the American College of Rheumatology (ACR) meeting being held Nov.
The annual ACR/ARHP meeting, which begins today, Sunday November 5th, is for many the premier meeting in rheumatology. The good news is that RheumNow and its expanded faculty will cover the meeting today and each day until Thursday. I haven’t missed an ACR meeting since 1984. In this span of 30 years I have acquired insights on how to navigate such a big meeting. When I say big, I mean over 15,000 attendees from over 100 countries swarming throughout a convention center that has the elements of the Texas state fair, Costco gone wild and a sold-out Margaritaville concert. Here's my ACR Playbook.
Ironwood Pharmaceuticals, Inc. (IRWD) today announced one oral and twelve poster presentations to be presented at the upcoming ACR/ARHP Annual Meeting in San Diego, California from November 3-8, 2017.
Dr. Jack Cush reviews the news and highlights from the past week on RheumNow.com. Hear about death and risk of lupus, tight control in Crohn's, risk of knee OA, new diagnostic tool for PMR, keeping infections low with biologics and new shingles vaccine, and infection concerns for San Diego.
Not unlike rheumatoid arthritis and other inflammatory disorders, therapeutic efficacy in Crohn's disease (CD) is often assessed clinically. There is growing use and interest in biomarkers of intestinal inflammation, such as faecal calprotectin and C-reactive protein.
One-third of adults in the USA experience chronic pain and take prescription nonsteroidal anti-inflammatory drugs (NSAIDs), acetaminophen, or opioids.
Clinically meaningful improvements in systemic sclerosis among patients treated with subcutaneous tocilizumab (Actemra) persisted during the open-label phase of a multinational randomized phase II trial, researchers reported.
Even though Arkansas lies on the edge of the geographic range of the principal Lyme disease tick vector, Ixodes scapularis, the risk for Lyme infection is low, and no confirmed Lyme disease cases were reported in Arkansas during 2008–2014 (1)
The European League Against Rheumatism and the American College of Rheumatology (EULAR/ACR) have developed classification criteria for idiopathic inflammatory myopathies (IIM) based on data from 976 IIM patients (74% adults; 26% children) and 624 non-IIM patients with mimicking conditions (82% ad
The Annals of Internal Medicine reports that despite improving trends in mortality, death rates from systematic lupus erythematosus (lupus) remain high compared to those in the general population, and disparities persist between subpopulations and geographic regions. Underreporting of lupus on death certificates may have resulted in underestimates of mortality rates.
PNAS reports that ANCA induced neutrophil activation, generation of neutrophil extracellular traps (NETS), and vasculitis are regulated by necroptosis. Using inhibitors of necroptosis-inducing kinases they were able to prevent ANCA associated vasculitis (AAV) in animal models.
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
